Sangamo (SGMO) director Jain discloses 253,003 shares and option grants

Rhea-AI Filing Summary

Sangamo Therapeutics (SGMO) director and Principal Accounting Officer Nikunj Jain reported initial beneficial ownership on 10/01/2025. He directly holds 253,003 shares of common stock and multiple stock options exercisable between 10/07/2031 and 02/24/2035, covering a total of 333,454 underlying shares listed in the filing. Several equity awards are time‑based and subject to continued service and standard vesting schedules; some RSUs remain unvested with staggered quarterly vesting through 02/24/2026. The filing was signed by an attorney‑in‑fact on 10/09/2025.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Jain Nikunj

(Last) (First) (Middle)

C/O SANGAMO THERAPEUTICS, INC.

501 CANAL BOULEVARD

(Street)

RICHMOND CA 94804

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
10/01/2025

3. Issuer Name and Ticker or Trading Symbol
SANGAMO THERAPEUTICS, INC [ SGMO ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Principal Accounting Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	253,003(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(2)	10/07/2031	Common Stock	45,608	$8.77	D
Stock Option (Right to Buy)	(2)	10/07/2031	Common Stock	11,892	$8.77	D
Stock Option (Right to Buy)	(3)	02/24/2032	Common Stock	24,750	$5.9	D
Stock Option (Right to Buy)	(4)	02/23/2033	Common Stock	3,237	$2.66	D
Stock Option (Right to Buy)	(4)	02/23/2033	Common Stock	48,513	$2.66	D
Stock Option (Right to Buy)	(4)	02/24/2035	Common Stock	99,454	$0.9561	D

Explanation of Responses:

1. Includes (a) 3,235 shares subject to the Reporting Person's February 24, 2023 restricted stock unit ("RSU") grant that will vest in successive equal quarterly installments through February 24, 2026; (b) 37,500 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026; and (c) 49,726 shares subject to the Reporting Person's February 25, 2025 RSU grant will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through each such date and subject to acceleration as provided in the 2018 EIP.

2. One-quarter (1/4) of the shares subject to the option vested and became exercisable on the first anniversary of the grant date, and the remainder of the shares subject to the option vest and become exercisable in 36 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

3. Fully vested

4. One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

	/s/ Scott B. Willoughby, Attorney-in-Fact	10/09/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What holdings did Nikunj Jain disclose on Form 3 for SGMO?

The filing shows 253,003 shares of common stock directly owned plus stock options that underlie 333,454 additional common shares exercisable through 02/24/2035.

What titles does the reporting person hold at Sangamo (SGMO)?

The form lists the reporting person as a Director and the company's Principal Accounting Officer.

Are any of the reported equity awards unvested and subject to service conditions?

Yes. The filing discloses RSUs and options with staged vesting schedules that require Continuous Service and include vesting through 02/24/2026 for some RSUs.

When do the disclosed options become exercisable or expire?

Exercise/expiration dates for the options in the filing range from 10/07/2031 to 02/24/2035, with specific series listed in the filing and individual exercise prices disclosed.

Who signed the Form 3 and when was it signed?

The filing is signed by Scott B. Willoughby, Attorney‑in‑Fact and dated 10/09/2025.